Improving Method Transfer Outcomes
14 March 2025 | By
A collaboration with Pfizer to create a tool to ensuring seamless method transfer between labs.
List view / Grid view
14 March 2025 | By
A collaboration with Pfizer to create a tool to ensuring seamless method transfer between labs.
Investment in the new manufacturing plant strengthens Merck (MSD)’s vaccine production capacity in the US.
7 March 2025 | By Fujifilm Wako
Discover the benefits of sustainable recombinant LAL for endotoxin testing. Learn about its relevance, selection considerations, and seamless integration into your lab processes with expert insights.
The analysis from the US Pharmacopeia (USP) provides a mitigation strategy for manufacturers and other stakeholders to improve reliability of medicines amidst supply chain challenges.
5 March 2025 | By PPD™ clinical research business of Thermo Fisher Scientific
This webinar will provide guidance in navigating the terrain of pharmacovigilance, including regulatory challenges, and gain a deeper understanding of the pivotal role played by safety reporting in clinical research.
The Committee for Medicinal Products for Human Use (CHMP) recommended approval of four new medicines plus the extension of therapeutic indications for 16 medicines.
4 March 2025 | By
PTC Therapeutics accelerates drug discovery process by integrating physicochemical property predictions into their Dotmatics ELN.
To mark Rare Disease Day 2025, EPR interviewed Christina Gkousgkouni, Head of Rare Diseases for Central South Europe, Sanofi.
The research suggests that the innovative 3D printing method has “great” potential for personalised treatments of intestinal inflammatory diseases.
The agency’s decision means eligible adult patients in the UK are set to access the combination immunotherapy as a new treatment option for acute lymphoblastic leukaemia (ALL).
24 February 2025 | By Adragos Pharma
Selecting the right Fill & Finish CDMO can make or break a product’s commercial success. In this webinar, join industry experts to explore key strategies for navigating this crucial stage, ensuring optimal efficiency where it matters most.
Developed and manufactured under a Manufacturer’s ‘Specials’ Licence (MSL), the gene therapy could provide a novel treatment option for paediatric patients at the earliest stage of the rare eye disease.
Ahead of the Critical Medicines Act anticipated in 2025, Teva’s report offers policy recommendations to mitigate the economic pressures risking generic medicine availability in Europe.
The paper highlights a new analytical method that provides potential for sustainable use of nanomaterials and unique benefits compared to other spectrofluorimetric techniques.
17 February 2025 | By ACD Labs
Process chemists can increase their efficiency by accessing process, analytical, and chemical data from across their organization using Luminata.